'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Survival Gains In Third Line Patients

 
• By Andrew McConaghie
  
Gilead HQ
Gilead's $21bn acquisition of Immunomedics is set for completion by the end of 2020.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category